The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...

These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Sorry, we have no data ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...